Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
Dan Liu,1 Jing-Jie Bai,2 Jun-Jie Yao,1 Yong-Bo Wang,1 Tong Chen,1 Qian Xing,1 Ran Bai1 1Department of Endocrinology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Department of Endocrinology, Dalian Children’s Hospital, Dal...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7b7924b7e01445ee8fbe887c3c0c385f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Dan Liu,1 Jing-Jie Bai,2 Jun-Jie Yao,1 Yong-Bo Wang,1 Tong Chen,1 Qian Xing,1 Ran Bai1 1Department of Endocrinology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Department of Endocrinology, Dalian Children’s Hospital, Dalian, Liaoning, People’s Republic of ChinaCorrespondence: Dan Liu; Ran BaiDepartment of Endocrinology, First Affiliated Hospital of Dalian Medical University, Zhongshan Str.222, Dalian, 116011, People’s Republic of ChinaEmail liudandan303114@163.com; bairan5556@163.comPurpose: To assess the association of type 2 diabetes mellitus (T2DM) and insulin glargine treatment with bone mineral density (BMD) in Chinese people.Methods: This retrospective study included 50 subjects with T2DM: 25 received oral glucose-lowering medication (ORL group), and 25 received oral glucose-lowering medication in combination with insulin glargine injection (CGI group). Thirty non-diabetic control subjects were also included. BMD was measured at lumbar vertebrae 1– 4 (L1–L4), spine bone mineral density (sBMD) results summary (L2–L4), femoral neck and trochanter by dual-energy x-ray absorptiometry.Results: Compared with non-diabetic controls, people with T2DM had significantly lower mean BMD at L2 (1.073± 0.120 vs 0.984± 0.158), L3 (1.094± 0.129 vs 0.991± 0.163) and L4 (1.089± 0.130 vs 0.982± 0.165) (all P< 0.05), significantly lower levels of serum calcium (2.02± 0.22 vs 2.27± 0.17 mmol/L, P< 0.05), PTH (24.19± 9.71 vs 31.52± 8.96 pg/mL, P< 0.05), and higher serum phosphate levels (1.43± 0.37 vs 1.20± 0.15 mmol/L, P< 0.05). The CGI group had higher L2, L3 and L4 BMD and sBMD (L2–L4) (P< 0.05), higher serum calcium levels (2.19± 0.11 vs 1.98± 0.20 mmol/L, P< 0.05) and lower serum phosphate levels (1.28± 0.20 vs 1.58± 0.43 mmol/L, P< 0.05) versus the ORL group. BMD and serum calcium levels were associated with the application of insulin glargine.Conclusion: These results suggest that insulin glargine may affect bone metabolism in patients diagnosed with T2DM. The study has implications for the selection of hypoglycemic agents for diabetic patients at risk of osteoporosis.Keywords: type 2 diabetes mellitus, insulin glargine, osteoporosis, bone mineral density |
|---|